Latest News

Uniseed Investee Hatchtech

AVCAL feature on Hatchtech featuring CEO Hugh Alsop and University of Melbourne Inventor Professor Vern Bowles.

Uniseed and MRCF invests AU$6.3m in respiratory start-up Innavac

Melbourne, Australia, 23 May, 2017 – Innavac Pty Ltd, a biotechnology company spun out of the University of Melbourne that is developing novel, synthetic Toll-like receptor (TLR) agonists as therapies for the prevention and treatment of respiratory infections, has...

Uniseed announces second investment from new fund – MetabloQ

MEDIA RELEASE   New drugs in development to starve cancer cells Revolutionary new cancer therapies for patients suffering with some of the most difficult-to-treat cancers are now being developed following a major discovery by scientists in the ACRF Centenary Cancer...

Uniseed makes new investment into drug development company Exonate Ltd

  Uniseed makes £200,000 investment in Exonate as part of £1.5 million round from existing and new investors Exonate awarded £4.9 million from the Wellcome Trust ‐ Seeding Drug Discovery Initiative Program to develop eye drop treatment for wet age‐related macular...

Exonate receives Wellcome Trust funding

Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)   Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need Cambridge, UK. Monday 6th February 2017 –...

Interested in our investees?
Contact us.